At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 103 enrolled
Drug / intervention
Acalabrutinib capsuledrug
Likely dose
Acalabrutinib capsule 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
In Brief
A Phase 4 clinical trial evaluating Acalabrutinib capsule for Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma. Completed, enrolled 103 participants across 15 sites.
Detailed Summary
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionMay 2023
TodayJul 2026
First PostedJun 18, 2021
Enrollment StartJul 14, 2021
Primary CompletionMay 2, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.0 years ago
Interventions
Acalabrutinib capsuledrug
The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily